Chinese biotech Innovent just dropped a huge win: their obesity drug mazdutide crushed Phase 3 trials. Here's what went down:

🎯 **The Numbers:**
- 18.55% average weight loss at Week 60 (vs 3.02% placebo)
- 44% of patients hit the 20%+ weight loss mark
- For non-diabetic patients? Even better—20.08% average drop

**The Kicker:** Liver fat content dropped 71.9% in the drug group vs a 5.1% increase in placebo. That's the kind of stuff that gets regulators excited.

**Safety Wins:** No new red flags. Most side effects were mild GI stuff that went away on their own. Only 2.9% quit due to adverse events.

Mazdutide's a dual GCG/GLP-1 agonist—think of it as a dual-action weight-loss mechanism hitting multiple pathways at once. Innovent's now gearing up to file with China's NMPA soon.

With GLP-1 mania still hot and obesity drugs in the spotlight, this could be a serious contender in the market. Chinese biotech + obesity drug + strong data = recipe for attention.